Advanced Search

    Technical Analysis for VERV - Verve Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 14.42 0.49% 0.07
    VERV closed up 0.49 percent on Friday, March 24, 2023, on 83 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical VERV trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 0.49%
    Wide Bands Range Expansion 0.49%
    Below Lower BB Weakness 0.49%
    Lower Bollinger Band Touch Weakness 0.49%
    Oversold Stochastic Weakness 0.49%
    Below Lower BB Weakness -5.26%
    Older End-of-Day Signals for VERV ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Up 1% about 9 hours ago
    60 Minute Opening Range Breakout about 14 hours ago
    Rose Above Lower Bollinger Band about 14 hours ago
    Down 3% about 14 hours ago
    Down 2 % about 14 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators Basic chart:

    Profile

    Verve Therapeutics, Inc. Description

    Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cardiovascular Disease Lipid Cholesterol Hypercholesterolemia Low Density Lipoprotein Pcsk9

    Is VERV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 5 Verve Therapeutics: VERVE-101 On Hold, But Technology Remains Sound
    Mar 4 Verve Therapeutics (NASDAQ:VERV) shareholders are up 4.6% this past week, but still in the red over the last year
    Mar 3 Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
    Mar 2 Verve Therapeutics GAAP EPS of -$0.67 beats by $0.09, revenue of $1.01M beats by $0.57M
    Mar 2 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
    Mar 1 Verve Therapeutics: Opportunity For Quick Profit On Eventual Lifting Of Clinical Hold
    Feb 15 3 Deeply Undervalued Stocks That Could Double Your Money
    Feb 14 Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
    Feb 6 2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023
    Feb 1 Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics
    See more VERV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 43.0
    52 Week Low 10.7
    Average Volume 708,399
    200-Day Moving Average 25.39
    50-Day Moving Average 19.97
    20-Day Moving Average 17.44
    10-Day Moving Average 16.28
    Average True Range 1.19
    RSI 28.57
    ADX 21.31
    +DI 13.53
    -DI 34.40
    Chandelier Exit (Long, 3 ATRs) 17.39
    Chandelier Exit (Short, 3 ATRs) 17.39
    Upper Bollinger Bands 20.53
    Lower Bollinger Band 14.34
    Percent B (%b) 0.01
    BandWidth 35.51
    MACD Line -1.39
    MACD Signal Line -1.15
    MACD Histogram -0.2464
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.56
    Resistance 3 (R3) 15.48 15.03 15.37
    Resistance 2 (R2) 15.03 14.74 15.07 15.31
    Resistance 1 (R1) 14.72 14.56 14.88 14.80 15.24
    Pivot Point 14.27 14.27 14.34 14.31 14.27
    Support 1 (S1) 13.96 13.98 14.12 14.04 13.60
    Support 2 (S2) 13.51 13.80 13.55 13.53
    Support 3 (S3) 13.20 13.51 13.47
    Support 4 (S4) 13.28